Department of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, CA, USA.
J Rheumatol. 2011 Aug;38(8):1720-7. doi: 10.3899/jrheum.110392.
The OMERACT patient reported outcomes (PRO) working group evaluated the methodologies for measuring responsiveness to change at the Outcome Measures in Rheumatology (OMERACT) 10 meeting. The outcome measures used in PRO studies are often expressed as continuous data at the group level (e.g., mean change in pain on a 0-100 visual analog scale). This is difficult to interpret and cannot easily be translated to the individual level of response. When interpreting scores at the individual level, it is important to take into account the following 4 main concepts: (1) improvement; (2) status of well-being; (3) onset of action; and (4) sustainability. Information from clinical trials on how many patients showed a response, what the level of response was, and how many patients are doing well, would be extremely useful for physicians. The objective of this article is to outline how continuous data may be reported in a clinically relevant manner. We will describe 5 techniques of reporting continuous variables in clinical studies and discuss the relevance of each.
OMERACT 患者报告结局(PRO)工作组在第 10 次结局测量在风湿病学(OMERACT)会议上评估了衡量变化反应的方法学。PRO 研究中使用的结局测量通常以群组水平的连续数据表示(例如,0-100 视觉模拟量表上疼痛的平均变化)。这很难解释,也不容易转化为个体反应水平。在解释个体水平的分数时,需要考虑以下 4 个主要概念:(1)改善;(2)幸福感状态;(3)作用开始;(4)可持续性。关于有多少患者表现出反应、反应水平如何以及有多少患者情况良好的临床试验信息对医生来说将非常有用。本文的目的是概述如何以临床相关的方式报告连续数据。我们将描述临床研究中报告连续变量的 5 种技术,并讨论每种技术的相关性。